Warning Letter: Palace Pharmacy
Warning Letter: Compounding at Palace Pharmacy
On March 23, the US Food and Drug Administration's (www.fda.gov) Denver, CO district office sent a warning letter to Palace Pharmacy (Lander, WY) concerning the company's drug-compounding activities.
The agency expressed special concern about Palace Pharmacy'sproduction of domperidone in 10-, 15-, and 20-mg capsules for humanuse. The letter noted that domperidone (sometimes used to increaseprolactin levels and improve breast milk production) is not approvedfor any human use in the United States, is not approved for enhancing lactation inany country, and has cardiovascular side effects that have forced itswitdrawal from the market in several countries where it had beenapproved to treat gastric stasis and gastropaiesis.
FDA warned Palace that the current domperidone label "fails to bearadequate direction for their use" and that the products themselves areunapproved drugs under 21 CFR § 201.115.
–Douglas McCormick
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
